Literature DB >> 10910068

Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer.

K Kawano1, S Gomi, K Tanaka, N Tsuda, T Kamura, K Itoh, A Yamada.   

Abstract

To help clarify the molecular basis of tumor immunology in lung cancer, we have investigated antigens recognized by HLA-A24-restricted CTLs established from T cells infiltrating into lung adenocarcinoma and report a new gene encoding tumor epitopes recognized by the CTLs. This gene was located on chromosome 4q31.22 and encoded an unreported endoplasmic reticulum-resident protein with 412 deduced amino acids. This protein had a molecular mass of 46 kDa and was expressed in the majority of malignant cells and tissues tested, with the exception of T-cell leukemia cells, but was not expressed in a panel of normal cells and tissues, except in those of the testis, placenta, and fetal liver. Two peptides at positions 13-20 and 75-84 were recognized by the CTLs and had an ability to induce HLA-A24-restricted and tumor-specific CTLs in peripheral blood mononuclear cells of lung cancer patients. Thus, these peptides might be appropriate molecules for use in the specific immunotherapy of HLA-A24+ patients with lung and other cancers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910068

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Lung cancer immunotherapy.

Authors:  Luis E Raez; Steven Fein; Eckhard R Podack
Journal:  Clin Med Res       Date:  2005-11

2.  Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution.

Authors:  Hamid Echchakir; Guillaume Dorothée; Isabelle Vergnon; Jeanne Menez; Salem Chouaib; Fathia Mami-Chouaib
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

3.  UDP-Gal: betaGlcNAc beta1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour.

Authors:  N Tsuda; Y Nonaka; S Shichijo; A Yamada; M Ito; Y Maeda; M Harada; T Kamura; K Itoh
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640

4.  Expression of tumor-rejection antigens in gynecologic cancers.

Authors:  S Tanaka; N Tsuda; K Kawano; M Sakamoto; T Nishida; T Hashimoto; S Shichijo; T Kamura; K Itoh
Journal:  Jpn J Cancer Res       Date:  2000-11

5.  Serine proteinase inhibitor 9 can be recognized by cytotoxic T lymphocytes of epithelial cancer patients.

Authors:  Koji Tanaka; Nanae Harashima; Fumihiko Niiya; Yoshiaki Miyagi; Naoya Hida; Mika Ochi; Nobue Imai; Mamoru Harada; Kyogo Itoh; Shigeki Shichijo
Journal:  Jpn J Cancer Res       Date:  2002-02

6.  Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.

Authors:  M Tamura; S Nishizaka; Y Maeda; M Ito; N Harashima; M Harada; S Shichijo; K Itoh
Journal:  Jpn J Cancer Res       Date:  2001-07

Review 7.  Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.

Authors:  Neftali Ortega Alarcon; Maddy Jaramillo; Heidi M Mansour; Bo Sun
Journal:  Pharmaceutics       Date:  2022-07-11       Impact factor: 6.525

Review 8.  Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.

Authors:  Paul Zolkind; Gavin P Dunn; Tianxiang Lin; Malachi Griffith; Obi L Griffith; Ravindra Uppaluri
Journal:  Oral Oncol       Date:  2016-10-14       Impact factor: 5.337

9.  Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients.

Authors:  Y Maeda; N Hida; F Niiya; K Katagiri; M Harada; H Yamana; T Kamura; M Takahashi; Y Sato; S Todo; K Itoh
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

10.  A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients.

Authors:  Y Sato; Y Maeda; H Shomura; T Sasatomi; M Takahashi; Y Une; M Kondo; T Shinohara; N Hida; K Katagiri; K Sato; M Sato; A Yamada; H Yamana; M Harada; K Itoh; S Todo
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.